Biotech · Private company · San Diego, CA, US
Starlight Cardiovascular Inc
Track this companyFree. Adds Starlight Cardiovascular Inc to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- Ductus Arteriosus StentCongenital Heart DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE StudyNA · RECRUITING · started Jan 16, 2026ClinicalTrials.gov NCT07114718 · fetched Nov 12, 2026
NIH awards8
- Commercialization Readiness of a Pulmonary Flow Restrictor for Hypoplastic Left Heart SyndromeFiscal year 2026 · $500KNIH RePORTER 1SB1HL184388-01 · fetched Nov 12, 2026
- DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROMEFiscal year 2026 · $1.2MNIH RePORTER 2R44HL162218-04 · fetched Nov 12, 2026
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITYFiscal year 2026 · $999.9KNIH RePORTER 5R44HL158304-05 · fetched Nov 12, 2026
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITYFiscal year 2025 · $999.9KNIH RePORTER 2R44HL158304-04A1 · fetched Nov 12, 2026
- DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROMEFiscal year 2025 · $999.9KNIH RePORTER 5R44HL162218-03 · fetched Nov 12, 2026
- Commercialization Readiness for Ductus Arteriosus Stent to Improve Congenital Heart Defect MortalityFiscal year 2024 · $500KNIH RePORTER 1SB1HL176266-01 · fetched Nov 12, 2026
- DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROMEFiscal year 2024 · $1MNIH RePORTER 2R44HL162218-02A1 · fetched Nov 12, 2026
- Administrative Supplement to Promote Diversity in MedTech Through Development of Pulmonary Flow RestrictorsFiscal year 2024 · $88.5KNIH RePORTER 3R44HL162218-02A1S1 · fetched Nov 12, 2026